{"ticker": {"uuid": "52361783-25ee-4011-b18f-90f00da8108b", "symbol": "TVRD", "name": "Tvardi Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Tvardi Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AJBVV95cUxQVk9DSHpOUjlVNGxHWmlsMlBxMjd3NzlkRk5QdjJ1M19rRllhSGxkREJ4SFFRSjVidi0yaUt2ZGJuVmVVTnhfR3BFUU1yM3c2QU0xdWlOSy1xbkM2ZExTb3F1ZjZGc2czMVg5bDVwbThOcV9RU1ZzWjlidjBlNWl5N1FvMTUxWGFMZ0dROXlNeXo2SnhEaXZENmxpU3NDR0VHY0FCc2xvUWhUR3NNcVBhNnpwcVFxTFozZFFPOVRXRkxBazRYWlF3U3lwR2tBNHFNLTJ5VXB6VkpWbFdmUG41OENNeWlORHViSlY3WDF5RjVxTDNrTE1IMHN0RmNRWG1pa0R1VG84bmdGeVUwdE5NU2xLSDJhaVI2N1RKcDFTMkRiUTdFd2xndWo5NUdGRHE2R3IzWG5kcEdYRUpjZnhHWDdaN1FBVm9vY01xbzZ4MER0Zmoz?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T21:09:06+00:00", "published_display": "13 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics, Inc. (NASDAQ: TVRD) Share Price, TVRD Stock News, TVRD Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE05elptU05JUzZDTGQtZjcwYWRMVm5Zc1Q4UFI0MXFoMy0ta2V5bkhFYzgwcldKLTBId19sbkJ3RHE3VWRRSlpXZTR4TzJNQlFVb2VlREpR?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T20:28:00+00:00", "published_display": "13 Jul 2026 20:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tvardi Therapeutics(TVRD) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxOVG9GRkFwYk1tb1JzRXozSUlPZG05a1RPdkhTOVNmeTZIZGFZY0ttVzdqeXZzUUJVVzJOaURMY0pDMWdmTkxQelQ5MmwzMnQ4azBsWFUtOFJWaUFRYjRnNDNIdkVZWWdLS2V0eXJpcU5MSU1SeTIyS2p4SEZBdlpZaWtmTDdRZXBpMHNDTzNUQTdWZ3lRSEVld0M2aW5BUWJKRlc0U3MzUFZIdHBCQTkwblhqbUk0RWlkOU1Fc2JVOVVpMmR5aWlfZXA3VU5jMGl2WmlPM1NFVE5YWUVPNmFTX2xDWnU2TW9QMklKQnRIRTcwSC1UaU9zYl91UGp4WTcxdG9wMEtYaE83bWI4WVZNT2FkTXMyY01Vdm5rbWZOWnNLZHJsY3pIemFR?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T02:33:26+00:00", "published_display": "13 Jul 2026 02:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics (TVRD) Registration filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPejZYOVRZY3JYQll2REhycTZselZOaW9lWEpUZndlZDNraW9wMHF1dTRkZ250NElTNHk4VkpVeE5rTEkweEw0QVhvSWx3bGVtbEFMU24wVWxZRExUbm1RMXN1S29BMFBfNzVhejhHb2NrbnRqYlpnX3duQVN1eWZlOHNlanYxdw?oc=5", "source_name": "Quartr", "published_at": "2026-07-11T03:10:21+00:00", "published_display": "11 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics (TVRD) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9VWjNYbngwZVU4d181a0RjeXhfNDc2aXpXaDNSZllIbnZGdmpzNl9PYmZHdzN4QzNLMUE4WDh0Umk3LUpLcDdWUXFJR3pKWG1TYW5pRkRPaUIzUUQxQklaN09ka3AwVml4Z0ZVRllBMWxRTnE0M050SkJ3ZWw?oc=5", "source_name": "Quartr", "published_at": "2026-07-11T03:09:17+00:00", "published_display": "11 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics (TVRD) Q4 2025 earnings summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE81VHFEZXMzUld4eDBGOXNDRjRhWE1qTW5GbjhfdmRoeXFYTk9ONVVKa1lYdDk3MFduZ0ozWlFwT01ON1VuS25qUzVpYkpEVE1NM09JaVlsOHRwVEV0Vng0MHlodWlXNG5Ta25hd1FTek9tM3NHNlE?oc=5", "source_name": "Quartr", "published_at": "2026-07-11T02:16:48+00:00", "published_display": "11 Jul 2026 02:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Tvardi Therapeutics Stock Falling Thursday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdzA1ZmJMbU1ta1Q3NVdTUkZGdGw3NVBTTTVVUG8tZnkyLUtRWDg4eFpnMndSdS02blQwRElMRUlkaHBtSmI1WjF0RmFkWUpqM1JBZkQ1NWlIQkhvNVBfNWdnd1FNcElkZ2xsQmNTSXNscmxycENUTzRLeWI2QnNpYkZGcWdMX3Q4TmlVQ0wzdlpEZXFQVjNpWWxrNzA0WUVieU9YbU5qYmxEUQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-09T13:06:53+00:00", "published_display": "09 Jul 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Upgrades Tvardi Therapeutics to Overweight From Neutral, Adjusts Price Target to $13 From $3", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/piper-sandler-upgrades-tvardi-therapeutics-113551436.html", "source_name": "MT Newswires", "published_at": "2026-07-09T11:35:51+00:00", "published_display": "09 Jul 2026 11:35", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Tvardi Therapeutics (TVRD.US)$ Respect it & it will Respect you", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNekdwZWZGbFZoTXM5eDdzaWhmSUk5bmFfYjlSa2g4d05sSldjbTBwczhYUzMyM0U4azQxVGExTEROZ2dVbzMzRExfSG5nUkVjd201Rm54VXJqb1ZGLThhUE1KYU5KcElhVGtvRHZQVW5rY0tkUE1KZS1xWHZjV1QwVHVfTm5ydWo3dDRyLU9VUEFQQWNMdnVkWmFtdDZKWWNOdVZicVAwUXl1ZmNkRi1kY0lB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T19:45:33+00:00", "published_display": "08 Jul 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tvardi Therapeutics (TVRD) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOWU14N29aa1RKM3MwZ1JRQTVIVGJkMHIyOHg4Q2t4SExCOE5Fb1NSTWlmZnY2VjRfQXNhbWZGX0EtbGVlekdtMU5yNWdETm0xenJQeklCVVZTN3BVc01MOFRaMGNVR2Y0VHgzRTFiQjFPV28yVUdIVTRoR1BmWjNURm95RTJGc1hUWGFqMGtn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T18:35:00+00:00", "published_display": "07 Jul 2026 18:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics, Inc. (NASDAQ:TVRD) stock jumps as Phase 1 data puts cash-value biotech under heavy churn", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNTHB4Z3h1eWVEVG9tTjNMRTlaR2V3dk1oaGJ3ZDNCNWtCZWg1Y3h0Z1FaREdUZ0tydGNWdGFJVXQ0WUZ6R2pMQmFUY0RXWVZpQ0NNZjlrdnVYWXpNc2psU1dxMi1RQ0dWUFV6aVh6V0w3TkkxTG1pWm1sYVRBOFpXdzlMOXFzcGlFZXlacjdTVFFzVVRUQ2Q2Q3FWM0tfN3dORTItQ1ZVR2pkeEdiZUxnanFXX0g5TlB0UmxuVHpKYVJUdVk?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-07T17:56:48+00:00", "published_display": "07 Jul 2026 17:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics\u2019 TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tvardi-therapeutics-tti-109-phase-110000747.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T11:00:00+00:00", "published_display": "07 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Tvardi Therapeutics Stock Gaining Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxObGJZVnlpOVAwZEEtWWRpSHJZczkzSUo4amRmcjFCMW9hbFpNelVBRXJOMjEzbGtndVhjME42b0FRWkRmbk9fV0ZXS3h0aHlSRHhNdmdZZWt6TW1lbHl0UVNCNHFxY3htcUgxMGlFUnZEdlo3aXBRWlR0TmRfY2FvZTIzS2UtQzB3M1g3MUp0T043eXpBTVFQMmJCbkFjdFMxdmJQb0d6Z0k?oc=5", "source_name": "Benzinga", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi says TTI-109 matched exposure, cut diarrhea in phase 1", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVXlZd0FSRTdGVEZFRDdNM0lmbUJDdllXSWNLb3NPeGJDMVFNd3I1V0dQNHFoTi1EY3A5Rnp3bTY5V3o0eUcwR29maGFhLTQwd25iOGtjTEVJQmJFTk9SeGlDR0ZFdGRkQVdXZHVTdk8tZjFwcVowYmVNdy1sbUdUY2lGMXU2QTV5U3lSSzdqTHlXUEx0VkFnZ2IxVjQ2M1FRTklkTDFVTW1nRnkxdVlicy1OUzZkZ25qdzREYg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics Inc. Actuals & Estimates (NASDAQ:TVRD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObGVZNWdaRlQ3bmF2SDJNRWIwSE5GSVZxUy0wUGFMSXFjQm10blRweUd3T1RIR3NiWEZxZnE0VWZFSlEyaTR0QV95VkhjYldGbXNUbTlXX1d0RDhCeHE1SHFzMFNXd0FXMGs0R2FOYlBNb2FhTUc4QnNwZzJRcHNIbzBrNWRsdw?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T04:10:42+00:00", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics to Participate in Upcoming Investor Events", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tvardi-therapeutics-participate-upcoming-investor-120000974.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T12:00:00+00:00", "published_display": "21 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tvardi: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tvardi-q1-earnings-snapshot-111127321.html", "source_name": "Associated Press", "published_at": "2026-05-08T11:11:27+00:00", "published_display": "08 May 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tvardi-therapeutics-announces-first-quarter-110000384.html", "source_name": "GlobeNewswire", "published_at": "2026-05-08T11:00:00+00:00", "published_display": "08 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tvardi Therapeutics (NASDAQ: TVRD) outlines 2026 votes on board, pay and auditors", "summary": "Tvardi Therapeutics (NASDAQ: TVRD) has released proxy materials for its 2026 virtual annual meeting on June 9, 2026, where shareholders will vote on the election of three Class II directors, a non-binding advisory \"say-on-pay\" resolution for executive compensation, and the freque", "url": "https://www.stocktitan.net/sec-filings/TVRD/def-14a-tvardi-therapeutics-inc-definitive-proxy-statement-617bde7ad752.html", "source_name": "Stock Titan", "published_at": "2026-04-24T16:09:53", "published_display": "24 Apr 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update", "summary": "Tvardi Therapeutics announced its financial and operating results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. Key milestones include anticipated topline data from its next-generation STAT3 inhibitor, TTI-109, in Q2 2026, and from ", "url": "https://www.globenewswire.com/news-release/2026/03/31/3265995/0/en/tvardi-therapeutics-announces-fourth-quarter-and-full-year-2025-results-and-provides-business-update.html", "source_name": "GlobeNewswire", "published_at": "2026-03-31T16:01:00", "published_display": "31 Mar 2026 16:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CARA Stock News Today | Earnings, Events & Price Alerts", "summary": "Cara Therapeutics (CARA) has been actively involved in corporate actions, including merger agreements and reverse stock splits. The company is set to merge with Tvardi Therapeutics, with the combined entity operating as Tvardi Therapeutics under the symbol \"TVRD\" after a 1-for-3 ", "url": "https://intellectia.ai/en/stock/CARA/news", "source_name": "Intellectia AI", "published_at": "2026-02-28T09:52:31", "published_display": "28 Feb 2026 09:52", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Begins Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World", "summary": "Barclays has initiated coverage on Tvardi Therapeutics (NASDAQ:TVRD). Other analysts, including Piper Sandler, BTIG Research, and Cantor Fitzgerald, have recently updated their ratings and price targets for the stock. The article also notes recent institutional investor activity ", "url": "https://www.defenseworld.net/2025/10/15/barclays-begins-coverage-on-tvardi-therapeutics-nasdaqtvrd.html", "source_name": "Defense World", "published_at": "2025-10-15T06:19:23", "published_display": "15 Oct 2025 06:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi's STAT3 inhibitor flunks phase 2 IPF trial amid high dropout rates", "summary": "Tvardi Therapeutics' STAT3 inhibitor, TTI-101, failed its phase 2 trial for idiopathic pulmonary fibrosis (IPF), showing placebo-like efficacy and high dropout rates primarily due to gastrointestinal adverse events. The company reported that lung function declined in patients rec", "url": "https://www.fiercebiotech.com/biotech/tvardis-stat3-inhibitor-flunks-phase-2-ipf-trial-amid-high-dropout-rates", "source_name": "Fierce Biotech", "published_at": "2025-10-13T09:25:00", "published_display": "13 Oct 2025 09:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics: Innovative Approaches to Fibrosis and Cancer - News and Statistics", "summary": "Tvardi Therapeutics is gaining attention in the biotech sector, with its stock up 32% this year due to its innovative approach to treating fibrosis and cancer. The company focuses on developing oral small-molecule drugs targeting the STAT3 protein, with its lead candidate, TTI-10", "url": "https://www.indexbox.io/blog/tvardi-therapeutics-a-rising-star-in-biotech/", "source_name": "IndexBox", "published_at": "2025-07-18T17:08:50", "published_display": "18 Jul 2025 17:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics (TVRD) Stock Price, News & Analysis $TVRD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBvYW1VR01zcWktRUp3dDVkT0s2aGZmcEd5UmQ2Rk5BOEJoTTZLd1lRbVFYaDJQODdVYjlVTTRTMFo4UWxqUjYzUjMyZnU1bDRZalBERGNQckplQQ?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-24T10:06:35+00:00", "published_display": "24 May 2025 10:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update", "summary": "Tvardi Therapeutics announced its Q1 2025 financial results and business updates, including the completion of its merger with Cara Therapeutics, which boosted its cash reserves. The company is well-financed into the second half of 2026 and expects multiple Phase 2 data readouts f", "url": "https://markets.financialcontent.com/worldnow.insideindianabusiness/article/bizwire-2025-5-13-tvardi-therapeutics-announces-first-quarter-2025-results-and-provides-business-update", "source_name": "FinancialContent", "published_at": "2025-05-13T16:05:00", "published_display": "13 May 2025 16:05", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics", "summary": "Tvardi Therapeutics has announced the completion of its merger with Cara Therapeutics, creating a Nasdaq-listed biopharmaceutical company. The combined entity, operating as Tvardi Therapeutics (NASDAQ: TVRD), will focus on developing treatments targeting STAT3 for fibrosis-driven", "url": "https://www.globenewswire.com/news-release/2025/04/15/3062122/0/en/tvardi-therapeutics-announces-closing-of-merger-with-cara-therapeutics.html", "source_name": "GlobeNewswire", "published_at": "2025-04-15T16:05:00", "published_display": "15 Apr 2025 16:05", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com", "summary": "Cara Therapeutics, nearing its merger with Tvardi Therapeutics and rebranding as Tvardi Therapeutics, Inc., has announced a 1-for-3 reverse stock split of its common stock. This move, approved by its board and stockholders, will take effect soon, reducing the number of outstandin", "url": "https://za.investing.com/news/company-news/cara-therapeutics-announces-1for3-reverse-stock-split-93CH-3656492", "source_name": "Investing.com South Africa", "published_at": "2025-04-14T17:58:00", "published_display": "14 Apr 2025 17:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics approves merger and stock plans By Investing.com", "summary": "Cara Therapeutics (NASDAQ: CARA) stockholders have approved a merger with Tvardi Therapeutics, Inc., alongside a reverse stock split, an increase in authorized shares, and new equity incentive and employee stock purchase plans. This strategic move aims to address Cara's financial", "url": "https://za.investing.com/news/sec-filings/cara-therapeutics-approves-merger-and-stock-plans-93CH-3636566", "source_name": "Investing.com South Africa", "published_at": "2025-04-01T22:36:00", "published_display": "01 Apr 2025 22:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc.", "summary": "Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., Esq., is investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) with Tvardi Therapeutics, Inc. Cara shareholders are expected to own approximately 17.0% of the comb", "url": "https://markets.financialcontent.com/worldnow.kwtv/article/bizwire-2025-2-20-cara-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-merger-of-cara-therapeutics-inc-cara", "source_name": "FinancialContent", "published_at": "2025-02-20T17:25:00", "published_display": "20 Feb 2025 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics Announces 1-for-12 Reverse Stock Split and Reduction in Authorized Shares", "summary": "Cara Therapeutics, Inc. has announced a 1-for-12 reverse stock split of its outstanding shares, effective December 30, 2024, at 5:00 p.m. ET, and a reduction in authorized shares from 200 million to approximately 16.67 million. This move is intended to help the company regain com", "url": "https://www.quiverquant.com/news/Cara+Therapeutics+Announces+1-for-12+Reverse+Stock+Split+and+Reduction+in+Authorized+Shares", "source_name": "Quiver Quantitative", "published_at": "2024-12-27T12:10:00", "published_display": "27 Dec 2024 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics accepts buyout from Houston's Tvardi Therapeutics, ending 20-year run in Connecticut", "summary": "Cara Therapeutics, a Connecticut-based company, has accepted a buyout offer from Houston's Tvardi Therapeutics, concluding its 20-year history in the state. This acquisition follows Cara Therapeutics laying off most of its employees and receiving FDA", "url": "https://www.ctpost.com/business/article/ct-stamford-cara-therapeutics-buyout-tvardi-19987789.php", "source_name": "CTPost", "published_at": "2024-12-18T22:11:19", "published_display": "18 Dec 2024 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement", "summary": "Cara Therapeutics and Tvardi Therapeutics have announced a definitive merger agreement to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on fibrosis-driven diseases. The combined entity, expected to operate as Tvardi Therapeutics, will leverage Tvardi's ", "url": "https://www.globenewswire.com/news-release/2024/12/18/2998930/0/en/cara-therapeutics-and-tvardi-therapeutics-announce-entry-into-merger-agreement.html", "source_name": "GlobeNewswire", "published_at": "2024-12-18T08:09:30", "published_display": "18 Dec 2024 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics and Tvardi Therapeutics To Merge", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPZ1ozd2RKaE02ZEtqTUhtUVBQeVhldE5XYVRlQVc1XzRZaUlpRVhCMFZPRi1sTHdXM0phNW5zcmRiTjRDRm1ZNU51YzN0QXFYR09GQnM5WE9uWkdNVFF4dEU3aXQxS0N3aENXbmwweVRVZTdTbS1JZlI2b0FWS1cyLTRac1RMSEZ5Mzg1LWlOZk1waVU?oc=5", "source_name": "citybiz", "published_at": "2024-12-18T08:00:00+00:00", "published_display": "18 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional owners may consider drastic measures as Cara Therapeutics, Inc.'s (NASDAQ:CARA) recent US$29m drop adds to long-term losses", "summary": "Institutional investors, primarily BlackRock and CSL Limited, own 65% of Cara Therapeutics, Inc. (NASDAQ:CARA), indicating significant influence. A recent US$29 million drop and a 68% one-year loss for shareholders suggest these institutions might take drastic measures, such as s", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cara/cara-therapeutics/news/institutional-owners-may-consider-drastic-measures-as-cara-t/amp", "source_name": "Simply Wall Street", "published_at": "2023-06-29T10:35:52", "published_display": "29 Jun 2023 10:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Tvardi Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AJBVV95cUxQVk9DSHpOUjlVNGxHWmlsMlBxMjd3NzlkRk5QdjJ1M19rRllhSGxkREJ4SFFRSjVidi0yaUt2ZGJuVmVVTnhfR3BFUU1yM3c2QU0xdWlOSy1xbkM2ZExTb3F1ZjZGc2czMVg5bDVwbThOcV9RU1ZzWjlidjBlNWl5N1FvMTUxWGFMZ0dROXlNeXo2SnhEaXZENmxpU3NDR0VHY0FCc2xvUWhUR3NNcVBhNnpwcVFxTFozZFFPOVRXRkxBazRYWlF3U3lwR2tBNHFNLTJ5VXB6VkpWbFdmUG41OENNeWlORHViSlY3WDF5RjVxTDNrTE1IMHN0RmNRWG1pa0R1VG84bmdGeVUwdE5NU2xLSDJhaVI2N1RKcDFTMkRiUTdFd2xndWo5NUdGRHE2R3IzWG5kcEdYRUpjZnhHWDdaN1FBVm9vY01xbzZ4MER0Zmoz?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T21:09:06+00:00", "published_display": "13 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics, Inc. (NASDAQ: TVRD) Share Price, TVRD Stock News, TVRD Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE05elptU05JUzZDTGQtZjcwYWRMVm5Zc1Q4UFI0MXFoMy0ta2V5bkhFYzgwcldKLTBId19sbkJ3RHE3VWRRSlpXZTR4TzJNQlFVb2VlREpR?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T20:28:00+00:00", "published_display": "13 Jul 2026 20:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics(TVRD) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxOVG9GRkFwYk1tb1JzRXozSUlPZG05a1RPdkhTOVNmeTZIZGFZY0ttVzdqeXZzUUJVVzJOaURMY0pDMWdmTkxQelQ5MmwzMnQ4azBsWFUtOFJWaUFRYjRnNDNIdkVZWWdLS2V0eXJpcU5MSU1SeTIyS2p4SEZBdlpZaWtmTDdRZXBpMHNDTzNUQTdWZ3lRSEVld0M2aW5BUWJKRlc0U3MzUFZIdHBCQTkwblhqbUk0RWlkOU1Fc2JVOVVpMmR5aWlfZXA3VU5jMGl2WmlPM1NFVE5YWUVPNmFTX2xDWnU2TW9QMklKQnRIRTcwSC1UaU9zYl91UGp4WTcxdG9wMEtYaE83bWI4WVZNT2FkTXMyY01Vdm5rbWZOWnNLZHJsY3pIemFR?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T02:33:26+00:00", "published_display": "13 Jul 2026 02:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics (TVRD) Registration filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPejZYOVRZY3JYQll2REhycTZselZOaW9lWEpUZndlZDNraW9wMHF1dTRkZ250NElTNHk4VkpVeE5rTEkweEw0QVhvSWx3bGVtbEFMU24wVWxZRExUbm1RMXN1S29BMFBfNzVhejhHb2NrbnRqYlpnX3duQVN1eWZlOHNlanYxdw?oc=5", "source_name": "Quartr", "published_at": "2026-07-11T03:10:21+00:00", "published_display": "11 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics (TVRD) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9VWjNYbngwZVU4d181a0RjeXhfNDc2aXpXaDNSZllIbnZGdmpzNl9PYmZHdzN4QzNLMUE4WDh0Umk3LUpLcDdWUXFJR3pKWG1TYW5pRkRPaUIzUUQxQklaN09ka3AwVml4Z0ZVRllBMWxRTnE0M050SkJ3ZWw?oc=5", "source_name": "Quartr", "published_at": "2026-07-11T03:09:17+00:00", "published_display": "11 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics (TVRD) Q4 2025 earnings summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE81VHFEZXMzUld4eDBGOXNDRjRhWE1qTW5GbjhfdmRoeXFYTk9ONVVKa1lYdDk3MFduZ0ozWlFwT01ON1VuS25qUzVpYkpEVE1NM09JaVlsOHRwVEV0Vng0MHlodWlXNG5Ta25hd1FTek9tM3NHNlE?oc=5", "source_name": "Quartr", "published_at": "2026-07-11T02:16:48+00:00", "published_display": "11 Jul 2026 02:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Tvardi Therapeutics Stock Falling Thursday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdzA1ZmJMbU1ta1Q3NVdTUkZGdGw3NVBTTTVVUG8tZnkyLUtRWDg4eFpnMndSdS02blQwRElMRUlkaHBtSmI1WjF0RmFkWUpqM1JBZkQ1NWlIQkhvNVBfNWdnd1FNcElkZ2xsQmNTSXNscmxycENUTzRLeWI2QnNpYkZGcWdMX3Q4TmlVQ0wzdlpEZXFQVjNpWWxrNzA0WUVieU9YbU5qYmxEUQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-09T13:06:53+00:00", "published_display": "09 Jul 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Upgrades Tvardi Therapeutics to Overweight From Neutral, Adjusts Price Target to $13 From $3", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/piper-sandler-upgrades-tvardi-therapeutics-113551436.html", "source_name": "MT Newswires", "published_at": "2026-07-09T11:35:51+00:00", "published_display": "09 Jul 2026 11:35", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Tvardi Therapeutics (TVRD.US)$ Respect it & it will Respect you", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNekdwZWZGbFZoTXM5eDdzaWhmSUk5bmFfYjlSa2g4d05sSldjbTBwczhYUzMyM0U4azQxVGExTEROZ2dVbzMzRExfSG5nUkVjd201Rm54VXJqb1ZGLThhUE1KYU5KcElhVGtvRHZQVW5rY0tkUE1KZS1xWHZjV1QwVHVfTm5ydWo3dDRyLU9VUEFQQWNMdnVkWmFtdDZKWWNOdVZicVAwUXl1ZmNkRi1kY0lB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T19:45:33+00:00", "published_display": "08 Jul 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tvardi Therapeutics (TVRD) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOWU14N29aa1RKM3MwZ1JRQTVIVGJkMHIyOHg4Q2t4SExCOE5Fb1NSTWlmZnY2VjRfQXNhbWZGX0EtbGVlekdtMU5yNWdETm0xenJQeklCVVZTN3BVc01MOFRaMGNVR2Y0VHgzRTFiQjFPV28yVUdIVTRoR1BmWjNURm95RTJGc1hUWGFqMGtn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T18:35:00+00:00", "published_display": "07 Jul 2026 18:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics, Inc. (NASDAQ:TVRD) stock jumps as Phase 1 data puts cash-value biotech under heavy churn", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNTHB4Z3h1eWVEVG9tTjNMRTlaR2V3dk1oaGJ3ZDNCNWtCZWg1Y3h0Z1FaREdUZ0tydGNWdGFJVXQ0WUZ6R2pMQmFUY0RXWVZpQ0NNZjlrdnVYWXpNc2psU1dxMi1RQ0dWUFV6aVh6V0w3TkkxTG1pWm1sYVRBOFpXdzlMOXFzcGlFZXlacjdTVFFzVVRUQ2Q2Q3FWM0tfN3dORTItQ1ZVR2pkeEdiZUxnanFXX0g5TlB0UmxuVHpKYVJUdVk?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-07T17:56:48+00:00", "published_display": "07 Jul 2026 17:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics\u2019 TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tvardi-therapeutics-tti-109-phase-110000747.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T11:00:00+00:00", "published_display": "07 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Tvardi Therapeutics Stock Gaining Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxObGJZVnlpOVAwZEEtWWRpSHJZczkzSUo4amRmcjFCMW9hbFpNelVBRXJOMjEzbGtndVhjME42b0FRWkRmbk9fV0ZXS3h0aHlSRHhNdmdZZWt6TW1lbHl0UVNCNHFxY3htcUgxMGlFUnZEdlo3aXBRWlR0TmRfY2FvZTIzS2UtQzB3M1g3MUp0T043eXpBTVFQMmJCbkFjdFMxdmJQb0d6Z0k?oc=5", "source_name": "Benzinga", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi says TTI-109 matched exposure, cut diarrhea in phase 1", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVXlZd0FSRTdGVEZFRDdNM0lmbUJDdllXSWNLb3NPeGJDMVFNd3I1V0dQNHFoTi1EY3A5Rnp3bTY5V3o0eUcwR29maGFhLTQwd25iOGtjTEVJQmJFTk9SeGlDR0ZFdGRkQVdXZHVTdk8tZjFwcVowYmVNdy1sbUdUY2lGMXU2QTV5U3lSSzdqTHlXUEx0VkFnZ2IxVjQ2M1FRTklkTDFVTW1nRnkxdVlicy1OUzZkZ25qdzREYg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics Inc. Actuals & Estimates (NASDAQ:TVRD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObGVZNWdaRlQ3bmF2SDJNRWIwSE5GSVZxUy0wUGFMSXFjQm10blRweUd3T1RIR3NiWEZxZnE0VWZFSlEyaTR0QV95VkhjYldGbXNUbTlXX1d0RDhCeHE1SHFzMFNXd0FXMGs0R2FOYlBNb2FhTUc4QnNwZzJRcHNIbzBrNWRsdw?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T04:10:42+00:00", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics to Participate in Upcoming Investor Events", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tvardi-therapeutics-participate-upcoming-investor-120000974.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T12:00:00+00:00", "published_display": "21 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tvardi-q1-earnings-snapshot-111127321.html", "source_name": "Associated Press", "published_at": "2026-05-08T11:11:27+00:00", "published_display": "08 May 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tvardi-therapeutics-announces-first-quarter-110000384.html", "source_name": "GlobeNewswire", "published_at": "2026-05-08T11:00:00+00:00", "published_display": "08 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics (NASDAQ: TVRD) outlines 2026 votes on board, pay and auditors", "summary": "Tvardi Therapeutics (NASDAQ: TVRD) has released proxy materials for its 2026 virtual annual meeting on June 9, 2026, where shareholders will vote on the election of three Class II directors, a non-binding advisory \"say-on-pay\" resolution for executive compensation, and the freque", "url": "https://www.stocktitan.net/sec-filings/TVRD/def-14a-tvardi-therapeutics-inc-definitive-proxy-statement-617bde7ad752.html", "source_name": "Stock Titan", "published_at": "2026-04-24T16:09:53", "published_display": "24 Apr 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update", "summary": "Tvardi Therapeutics announced its financial and operating results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. Key milestones include anticipated topline data from its next-generation STAT3 inhibitor, TTI-109, in Q2 2026, and from ", "url": "https://www.globenewswire.com/news-release/2026/03/31/3265995/0/en/tvardi-therapeutics-announces-fourth-quarter-and-full-year-2025-results-and-provides-business-update.html", "source_name": "GlobeNewswire", "published_at": "2026-03-31T16:01:00", "published_display": "31 Mar 2026 16:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CARA Stock News Today | Earnings, Events & Price Alerts", "summary": "Cara Therapeutics (CARA) has been actively involved in corporate actions, including merger agreements and reverse stock splits. The company is set to merge with Tvardi Therapeutics, with the combined entity operating as Tvardi Therapeutics under the symbol \"TVRD\" after a 1-for-3 ", "url": "https://intellectia.ai/en/stock/CARA/news", "source_name": "Intellectia AI", "published_at": "2026-02-28T09:52:31", "published_display": "28 Feb 2026 09:52", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Begins Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World", "summary": "Barclays has initiated coverage on Tvardi Therapeutics (NASDAQ:TVRD). Other analysts, including Piper Sandler, BTIG Research, and Cantor Fitzgerald, have recently updated their ratings and price targets for the stock. The article also notes recent institutional investor activity ", "url": "https://www.defenseworld.net/2025/10/15/barclays-begins-coverage-on-tvardi-therapeutics-nasdaqtvrd.html", "source_name": "Defense World", "published_at": "2025-10-15T06:19:23", "published_display": "15 Oct 2025 06:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi's STAT3 inhibitor flunks phase 2 IPF trial amid high dropout rates", "summary": "Tvardi Therapeutics' STAT3 inhibitor, TTI-101, failed its phase 2 trial for idiopathic pulmonary fibrosis (IPF), showing placebo-like efficacy and high dropout rates primarily due to gastrointestinal adverse events. The company reported that lung function declined in patients rec", "url": "https://www.fiercebiotech.com/biotech/tvardis-stat3-inhibitor-flunks-phase-2-ipf-trial-amid-high-dropout-rates", "source_name": "Fierce Biotech", "published_at": "2025-10-13T09:25:00", "published_display": "13 Oct 2025 09:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics: Innovative Approaches to Fibrosis and Cancer - News and Statistics", "summary": "Tvardi Therapeutics is gaining attention in the biotech sector, with its stock up 32% this year due to its innovative approach to treating fibrosis and cancer. The company focuses on developing oral small-molecule drugs targeting the STAT3 protein, with its lead candidate, TTI-10", "url": "https://www.indexbox.io/blog/tvardi-therapeutics-a-rising-star-in-biotech/", "source_name": "IndexBox", "published_at": "2025-07-18T17:08:50", "published_display": "18 Jul 2025 17:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics (TVRD) Stock Price, News & Analysis $TVRD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBvYW1VR01zcWktRUp3dDVkT0s2aGZmcEd5UmQ2Rk5BOEJoTTZLd1lRbVFYaDJQODdVYjlVTTRTMFo4UWxqUjYzUjMyZnU1bDRZalBERGNQckplQQ?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-24T10:06:35+00:00", "published_display": "24 May 2025 10:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update", "summary": "Tvardi Therapeutics announced its Q1 2025 financial results and business updates, including the completion of its merger with Cara Therapeutics, which boosted its cash reserves. The company is well-financed into the second half of 2026 and expects multiple Phase 2 data readouts f", "url": "https://markets.financialcontent.com/worldnow.insideindianabusiness/article/bizwire-2025-5-13-tvardi-therapeutics-announces-first-quarter-2025-results-and-provides-business-update", "source_name": "FinancialContent", "published_at": "2025-05-13T16:05:00", "published_display": "13 May 2025 16:05", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics", "summary": "Tvardi Therapeutics has announced the completion of its merger with Cara Therapeutics, creating a Nasdaq-listed biopharmaceutical company. The combined entity, operating as Tvardi Therapeutics (NASDAQ: TVRD), will focus on developing treatments targeting STAT3 for fibrosis-driven", "url": "https://www.globenewswire.com/news-release/2025/04/15/3062122/0/en/tvardi-therapeutics-announces-closing-of-merger-with-cara-therapeutics.html", "source_name": "GlobeNewswire", "published_at": "2025-04-15T16:05:00", "published_display": "15 Apr 2025 16:05", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com", "summary": "Cara Therapeutics, nearing its merger with Tvardi Therapeutics and rebranding as Tvardi Therapeutics, Inc., has announced a 1-for-3 reverse stock split of its common stock. This move, approved by its board and stockholders, will take effect soon, reducing the number of outstandin", "url": "https://za.investing.com/news/company-news/cara-therapeutics-announces-1for3-reverse-stock-split-93CH-3656492", "source_name": "Investing.com South Africa", "published_at": "2025-04-14T17:58:00", "published_display": "14 Apr 2025 17:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics approves merger and stock plans By Investing.com", "summary": "Cara Therapeutics (NASDAQ: CARA) stockholders have approved a merger with Tvardi Therapeutics, Inc., alongside a reverse stock split, an increase in authorized shares, and new equity incentive and employee stock purchase plans. This strategic move aims to address Cara's financial", "url": "https://za.investing.com/news/sec-filings/cara-therapeutics-approves-merger-and-stock-plans-93CH-3636566", "source_name": "Investing.com South Africa", "published_at": "2025-04-01T22:36:00", "published_display": "01 Apr 2025 22:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc.", "summary": "Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., Esq., is investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) with Tvardi Therapeutics, Inc. Cara shareholders are expected to own approximately 17.0% of the comb", "url": "https://markets.financialcontent.com/worldnow.kwtv/article/bizwire-2025-2-20-cara-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-merger-of-cara-therapeutics-inc-cara", "source_name": "FinancialContent", "published_at": "2025-02-20T17:25:00", "published_display": "20 Feb 2025 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics Announces 1-for-12 Reverse Stock Split and Reduction in Authorized Shares", "summary": "Cara Therapeutics, Inc. has announced a 1-for-12 reverse stock split of its outstanding shares, effective December 30, 2024, at 5:00 p.m. ET, and a reduction in authorized shares from 200 million to approximately 16.67 million. This move is intended to help the company regain com", "url": "https://www.quiverquant.com/news/Cara+Therapeutics+Announces+1-for-12+Reverse+Stock+Split+and+Reduction+in+Authorized+Shares", "source_name": "Quiver Quantitative", "published_at": "2024-12-27T12:10:00", "published_display": "27 Dec 2024 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics accepts buyout from Houston's Tvardi Therapeutics, ending 20-year run in Connecticut", "summary": "Cara Therapeutics, a Connecticut-based company, has accepted a buyout offer from Houston's Tvardi Therapeutics, concluding its 20-year history in the state. This acquisition follows Cara Therapeutics laying off most of its employees and receiving FDA", "url": "https://www.ctpost.com/business/article/ct-stamford-cara-therapeutics-buyout-tvardi-19987789.php", "source_name": "CTPost", "published_at": "2024-12-18T22:11:19", "published_display": "18 Dec 2024 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement", "summary": "Cara Therapeutics and Tvardi Therapeutics have announced a definitive merger agreement to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on fibrosis-driven diseases. The combined entity, expected to operate as Tvardi Therapeutics, will leverage Tvardi's ", "url": "https://www.globenewswire.com/news-release/2024/12/18/2998930/0/en/cara-therapeutics-and-tvardi-therapeutics-announce-entry-into-merger-agreement.html", "source_name": "GlobeNewswire", "published_at": "2024-12-18T08:09:30", "published_display": "18 Dec 2024 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cara Therapeutics and Tvardi Therapeutics To Merge", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPZ1ozd2RKaE02ZEtqTUhtUVBQeVhldE5XYVRlQVc1XzRZaUlpRVhCMFZPRi1sTHdXM0phNW5zcmRiTjRDRm1ZNU51YzN0QXFYR09GQnM5WE9uWkdNVFF4dEU3aXQxS0N3aENXbmwweVRVZTdTbS1JZlI2b0FWS1cyLTRac1RMSEZ5Mzg1LWlOZk1waVU?oc=5", "source_name": "citybiz", "published_at": "2024-12-18T08:00:00+00:00", "published_display": "18 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional owners may consider drastic measures as Cara Therapeutics, Inc.'s (NASDAQ:CARA) recent US$29m drop adds to long-term losses", "summary": "Institutional investors, primarily BlackRock and CSL Limited, own 65% of Cara Therapeutics, Inc. (NASDAQ:CARA), indicating significant influence. A recent US$29 million drop and a 68% one-year loss for shareholders suggest these institutions might take drastic measures, such as s", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cara/cara-therapeutics/news/institutional-owners-may-consider-drastic-measures-as-cara-t/amp", "source_name": "Simply Wall Street", "published_at": "2023-06-29T10:35:52", "published_display": "29 Jun 2023 10:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 43, "sentiment_summary": {"positive": 7, "negative": 2, "neutral": 34, "score": 53, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 5.85, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 4.4, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 3.28, "latest_week": "2026-07-10", "one_week_move": 62.4, "four_week_move": 24.2, "twelve_week_move": -3.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.091866, "market_dynamics_buy_signal": false, "relative_strength": -74.724375, "fair_value_gap": -85.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.5036, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+62.4% over one week, +24.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "GlobeNewswire", "count": 6}, {"label": "Market source", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "Quartr", "count": 3}, {"label": "Benzinga", "count": 2}, {"label": "Quiver Quantitative", "count": 2}, {"label": "Stock Titan", "count": 2}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 8}, {"label": "Analyst action", "count": 2}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+62.4% over one week, +24.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Tvardi Therapeutics Company Profile & Introduction"}], "updated_at": "2026-07-16T02:16:44.823843+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}